| DHR |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$1.88 vs. cons $1.84 |
MEDIUM |
| DHR |
Report |
Core/Organic Revenue Growth (Q2 2026) |
BEAT |
pred ~2.4% vs. cons 2.0% |
MEDIUM |
| DHR |
Report |
Adjusted Operating Margin (Q2 2026) |
BEAT |
pred ~26.9% vs. cons 26.5% |
MEDIUM |
| DHR |
Guide |
FY2026 Adjusted EPS Guidance |
BETTER |
guide ~$8.45-$8.65 vs. cons $8.46 (FY2026) |
MEDIUM |
| DHR |
Guide |
FY2026 Core Revenue Growth Guidance |
UNCHANGED |
guide ~3%-6% (reaffirmed, midpoint 4.5%) vs. cons 4.3% (FY2026) |
MEDIUM |
| DHR |
Guide |
Q3 2026 Core Revenue Growth / Margin Cadence Commentary |
BETTER |
guide ~mid-single-digit core growth (~4%) vs. cons ~3% (Q3 2026), with margin recovering toward ~28% from Q2's 26.5% |
LOW |
| DHR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| DHR |
Return |
5-day cumulative residual |
+1.2% (STABILIZE) |
A modest EPS/margin/core-growth beat plus reaffirmed-to-slightly-raised FY guidance (now incorporating Masimo) should produce a positive but not explosive day-1 pop, since the stock already rallied ~24% off May lows and much of the bioprocessing-recovery/Masimo-optimism is pre-priced after Agilent's and ICON's strong prints. Out-period math is a wash: while Q2 margin dip was pre-guided (no incremental cut), Masimo integration costs, incremental amortization (~$1.7B FY26), higher interest expense, and lingering China VBP/Cepheid respiratory drag temper analysts' out-quarter EPS raises even if headline adjusted EPS beats — capping upward revisions. Conversely, continued bioprocessing equipment-order momentum and confirmation that H1 headwinds are fading on schedule should prevent the kind of macro-driven post-print selloff seen after Q1 (when the stock fell ~9% despite a beat-and-raise). Net effect: gains from the print largely hold over the week rather than compounding meaningfully higher or reversing — a stabilization pattern. |
LOW |